1. Introduction {#s1}
===============

Methamphetamine is a lipophilic compound used recreationally for its ability to temporarily induce a variety of desirable effects, including increased energy levels, positive mood, euphoria, reduced appetite, weight loss, enhanced mental acuity, social, and sexual disinhibition (Cretzmeyer et al., [@B33]; Green and Halkitis, [@B62]; Cruickshank and Dyer, [@B34]).

According to the United Nations World Drug Report, between 0.3 and 1.3% of the world\'s population uses amphetamine-type stimulants (United Nations Office, [@B150]; Burns, [@B19]). Amphetamine abuse has a multitude of repercussions, including violence (Plüddemann et al., [@B119]) criminal behavior, incarceration, recidivism (Cartier et al., [@B22]), and the transmission of HIV (Halkitis et al., [@B66]; Colfax and Guzman, [@B30]).

Repeated administrations, or administration of high doses of methamphetamine, commonly leads to psychosis (Connell, [@B31]; Bell, [@B13]; Angrist and Gershon, [@B5]; Bell, [@B14]; Batki and Harris, [@B12]; Curran et al., [@B35]), where symptoms typically include paranoid delusions, auditory hallucinations, increased activity, and odd speech (Connell, [@B31]; Bramness et al., [@B17]). The prevalence of psychotic symptoms as a result of methamphetamine use can be difficult to determine as the diagnosis could be confused with that of a primary psychotic disorder, or other drug use (Weich and Pienaar, [@B154]; American Psychiatric Association, [@B4]). Depending on the study, the prevalence of psychosis in methamphetamine abusers ranges between 10 and 60% (Farrell et al., [@B44]; McKetin et al., [@B103]; Mahoney et al., [@B98]). In Thailand, approximately 10% of admissions to psychiatric facilities are attributed to methamphetamine related psychosis (Farrell et al., [@B44]). An Australian study of 277 non-treatment-seeking illicit methamphetamine users with no prior diagnosis of schizophrenia or other psychotic disorders found that 51 (18%) had "clinically significant" psychotic symptoms (McKetin et al., [@B103]), and a U.S. study of 42 cocaine-dependent and 43 methamphetamine-dependent individuals, screened to exclude patients with other axis I disorders, reported psychotic symptoms of at least some type in at least 60% of both groups (Mahoney et al., [@B98]). Recreational use of methamphetamine has been shown to increase the risk of developing psychotic symptoms by two to three fold (McKetin et al., [@B102]) especially if larger amounts of methamphetamine is used, or use began at a younger age (Chen et al., [@B28]).

Symptoms of MAP were originally thought to dissipate within a week of methamphetamine withdrawal (Connell, [@B31]). However, studies have shown that, although the large majority of MAP symptoms resolve within 1 month (Iwanami et al., [@B77]; Ujike and Sato, [@B149]; Deng et al., [@B39]), 30% of those with MAP had symptoms persist for up to 6 months (Deng et al., [@B39]), and 10--28% reported persisting symptoms for more than 6 months (Iwanami et al., [@B77]; Deng et al., [@B39]). Symptoms of MAP have been shown to relapse after long periods of abstinence (Sato et al., [@B128]; Yui et al., [@B161], [@B162]).

The DSM-V indicates that persistent psychosis after 6 months of abstinence from methamphetamine can constitute a diagnosis of schizophrenia (American Psychiatric Association, [@B4]). A recent Chinese study found that 5% of patients initially diagnosed with MAP had their diagnosis changed to schizophrenia in the interview conducted by the study (Deng et al., [@B39]). In Thailand, a similar study found that 38.8% of abstinent methamphetamine abusers who were initially hospitalized for MAP, were subsequently given a diagnosis of schizophrenia (Kittirattanapaiboon et al., [@B89]).

Whether there are fewer presentations of negative symptoms (lack of affect, social withdrawal) in MAP than schizophrenia (Tomiyama, [@B147]; Panenka et al., [@B113]), or whether both positive and negative symptom presentations are similar in MAP and schizophrenia (Srisurapanont et al., [@B139], [@B140]), is still under debate. However, there is broad consensus that the positive symptoms of psychosis induced by methamphetamine use are difficult to distinguish from the positive symptoms of schizophrenia (Connell, [@B31]; Janowsky and Risch, [@B81]; Bramness et al., [@B17]; Medhus et al., [@B104]).

Clinical similarities between MAP and schizophrenia have long since been recognized (Connell, [@B31]). Various methamphetamine induced animal models for psychosis such as the neurotoxicity model (Robinson and Becker, [@B123]; Machiyama, [@B97]; Davidson et al., [@B37]; Cadet and Krasnova, [@B21]), the behavioral sensitization model (Castner and Goldman-Rakic, [@B24]; Featherstone et al., [@B45]), or the escalating dose-binge model (Segal and Kuczenski, [@B131], [@B132]), have been proposed and debated for validity. Most relevant to this review is the methamphetamine sensitization model, where lower doses of repeated methamphetamine exposure have been shown to produce behavioral effects that best model psychosis by measurements such as increased locomotion, hallucinatory behaviors in the case of non-human primates, and deficits in pre-pulse inhibition, latent inhibition, and other cognitive measures in a variety of animal models (Castner and Goldman-Rakic, [@B24]; Kamei et al., [@B84]; Featherstone et al., [@B45]; Nagai et al., [@B108]; Forrest et al., [@B46]).

Schizophrenia has been associated with a wide variety of neurocognitive deficits e.g., in verbal memory, social cognition, implicit learning, and working memory, which impair day to day function (Green, [@B63]; Gold, [@B53]; Horan et al., [@B70]). Cognitive functions such as working memory rely on coherent interaction between interaction between interneurons and pyramidal cells, which form local memory fields, and "sharpen" signal to noise ratios (Goldman-Rakic, [@B57]). GABAergic interneurons in the cortex shape the stimulus response properties of pyramidal cells, and prevent aberrant firing of cortical processes (Jones, [@B82]). Evidence for GABA dysfunction in schizophrenia is convincing, and has been reviewed extensively (Goldman-Rakic, [@B56]; Lewis et al., [@B95]; Daskalakis et al., [@B36]; Lewis et al., [@B94]).

If MAP is to be a good model for schizophrenia, it should also exhibit similar cognitive impairments, and similar evidence of GABA disturbances as schizophrenia. In humans, MAP presents with similar cognitive impairments as those in schizophrenia, such as deficits in verbal and working memory, as well as other executive functions (Scott et al., [@B130]; Jacobs et al., [@B80]). In animal models, cognitive impairments have been found in using the amphetamine sensitization model in the non-human primate (Castner et al., [@B25]), and rodents (Nagai et al., [@B108]; Arai et al., [@B8]). Indeed, emerging evidence that will be discussed in this paper suggests that the cognitive deficits in MAP may also result from a GABAergic dysfunction in the cortex, although the mechanism for these observations are unknown.

The present paper will first describe the well characterized and relevant nigrostriatal, mesolimbic, and mesocortical pathways, on which methamphetamine exerts its major effects. Second, we will review the acute effects of methamphetamine and chronic effects of methamphetamine on these pathways. Next, studies that have shown cortical GABAergic disturbance will be discussed. Finally, we propose a possible vulnerability of GABAergic interneurons in the cortex to glutamate overflow, which might explain the GABAergic disturbance by methamphetamine that might lead to psychosis.

2. Neurocircuitry of the cortex and basal ganglia
=================================================

Methamphetamine appears to primarily affect the dopaminergic system. The present review will focus on the three main pathways, namely the nigrostriatal, mesolimbic, and mesocortical pathways, summarized in Figure [1](#F1){ref-type="fig"}.

![**Nigrostriatal, mesocortical, and mesolimbic pathways**. When cortical neurons activate the NMDA receptors on neurons of the direct pathway (*red*) in the striatum, striatal neurons are primed to send GABA signals to the SNr/GPi, which would inhibit the tonic GABA to the thalamus, allow glutamate signals to fire in the cortex, and further activate cortical neurons. The indirect pathway (*blue*) is primed when cortical neurons activate the NMDA receptors on the striatal neurons that express D~2~ receptors, which would send inhibitory signals to the globus pallidus externa (GPe), reduce GABA signaling to the STN, and stimulate the SNr/GPi to enhance GABA inhibiting of thalamocortical signaling. The mesolimbic pathway (*green*) consist of dopaminergic projections from the VTA to the NAcc, which sends inhibitory signals to the SNr/GPi. The mesocortical pathway (*orange*) consists of dopaminergic projections from the VTA to the cortex, innervating both pyramidal and non-pyramidal neurons which express D~1~ receptors. Reciprocal pathways (purple) from the cortex to the VTA and NAcc provide cortical feedback to subcortical structures. CTX, cortex; GABA, gamma-aminobutyric acid; NMDA, N-methyl-D-aspartate; GPe, globus pallidus externa; SNr, substantia nigra pars reticulata; GPi, globus pallidus interna; TH, thalamus; STN, sub thalamic nucleus; NAcc, nucleus accumbens core; VTA, ventral tegmental area. Round structures indicate dopamine cell bodies; star shaped structures indicate GABA cell bodies; triangular structures indicate glutamate cell bodies.](fnhum-08-00537-g0001){#F1}

The nigrostriatal pathway consists of the known direct and indirect pathways, which control the expression and direction of behavior to predictable stimuli or rewards (Balleine et al., [@B11]; Nicola, [@B110]). The mesolimbic pathway is involved in reward processing (Koob and Bloom, [@B90]), effort related functions (Salamone et al., [@B127]), translation of emotions into actions (Mogenson et al., [@B106]), and direction of behavior where stimuli and rewards are less predictable (Nicola, [@B110]). The mesocortical pathway is involved with cognitive functions such as working memory (Moal, [@B136]; Goldman-Rakic et al., [@B58]).

The majority (up to 77%) of the striatum consists of GABAergic projection neurons (Graveland et al., [@B61]), that receive topographical input from the cortex (Kemp and Powell, [@B88]; Alexander and Crutcher, [@B2]; Haber and Knutson, [@B64]), and express *N*-methyl-*D*-aspartate (NMDA) receptors (Albin et al., [@B1]). The projection neurons comprises two major sub-populations. The striatonigral neurons, characterized by the expression of D~1~ receptors, project to the basal ganglial output nuclei, substantia nigra pars reticulata (SNr)/globus pallidus interna (GPi) (Altar and Hauser, [@B3]), the starting point of the direct pathway. The striatopallidal neurons, characterized by the expression of D~2~ receptors, project to the globus pallidus externa (GPe), and begin the indirect pathway. In the indirect pathway, neurons in the (GPe) send GABAergic projections to the subthalamic nucleus (STN), which send glutamatergic projections to activate the SNr/GPi. The SNr consists of tonically active GABAergic neurons that project to the thalamus (Reubi et al., [@B121], [@B122]), and the thalamus projects via topographical glutamatergic neurons to the cortex (Haber and Knutson, [@B64]).

Since the SNr GABAergic neurons are tonically active (Reubi et al., [@B121], [@B122]), there is normally little movement at rest, or minimal signaling to the cortex from the thalamus. In addition, up to 23% of striatal neurons are interneurons which have inhibitory effects on the projection neurons (Rymar et al., [@B126]), further inhibiting thalamocortical signals at rest (Reubi et al., [@B121], [@B122]). Cortical glutamatergic activation of either the direct or indirect pathway primes the relevant pathway to an "upstate" (Wilson and Kawaguchi, [@B157]). From this "upstate," a small additional increase in activation by dopamine, released from the SNc, or a small decrease in inhibition by striatal cholinergic interneurons, will lead to the generation of action potentials that finally activate the primed pathway (Wilson, [@B156]; Tepper and Bolam, [@B145]).

Activation of the dopamine system enhances glutamate signaling in the cortex from the nigrostriatal and mesolimbic pathways, and increases dopamine in the prefrontal cortex from the mesocortical pathway (Figure [2](#F2){ref-type="fig"}).

![**Healthy effects of dopamine on dopaminergic pathways**. The substantia nigra pars compacta (SNc) releases dopamine into the striatum (large black arrows), and enhances thalamocortical glutamate release along the nigrostriatal pathway (*blue and red*). The direct pathway (*red*) becomes enhanced by D~1~ activation, and the indirect pathway (*blue*) becomes inhibited by D~2~ activation. Mesolimbic dopamine (*green*) to the NAc core increases GABA inhibition from the NAc core to the SNr/GPi, further increasing thalamocortical glutamate transmission. Mesocortical dopamine (*orange*) increases cortical pyramidal firing and simultaneously stimulates cortical interneurons, which sharpen the pyramidal signals to subcortical nuclei (*blue, red, and purple*). CTX, cortex; GABA, gamma-aminobutyric acid; NMDA, N-methyl-D-aspartate; GPe, globus pallidus externa; SNr, substantia nigra pars reticulata; GPi, globus pallidus interna; TH, thalamus; STN, sub thalamic nucleus; NAcc, nucleus accumbens core; VTA, ventral tegmental area. Round structures indicate dopamine cell bodies; star shaped structures indicate GABA cell bodies; triangular structures indicate glutamate cell bodies.](fnhum-08-00537-g0002){#F2}

Dopamine causes activation of neurons expressing D~1~ receptors, and inhibits neurons which express D~2~ receptors (Surmeier et al., [@B144]). In the nigrostriatal pathway, the synergistic activation of both the D~1~ and D~2~ receptors allows dopamine to enhance glutamate induced firing in the striatum (Hu and White, [@B72]). Thus, dopamine release into the striatum from the SNc enhances thalamocortical signals by simultaneously activating the direct pathway, and inhibiting the indirect pathway. Long term potentiation from this glutamatergic transmission leads to learning of the relevant activity, and the development of persistent behaviors (Yin and Knowlton, [@B160]; Balleine et al., [@B11]).

The mesolimbic pathway arises from dopaminergic ventral tegmental area (VTA) projections to the nucleus accumbens (NAc) (Fallon and Moore, [@B43]). The efferent projections of the NAc and afferent connections with other neuronal structures such as the amygdala, hippocampus and cortex are complex, and mediate its role in direction of behavior to emotive stimuli (Haber and McFarland, [@B65]; Haber and Knutson, [@B64]). Briefly, the NAc consists of "core" and "shell" regions, and one of the major effects of dopamine release at the NAc core is to increase GABA release to the SNr/GPi, disinhibiting the thalamus and increasing cortical glutamate (Maurice et al., [@B101]; Nicola, [@B110]).

The VTA and SN project to the cortex along the mesocortical pathway, and terminates on both pyramidal and non-pyramidal cells in the pre-frontal cortex (PFC) (Goldman-Rakic et al., [@B59]; Williams and Goldman-Rakic, [@B155]; Tzschentke, [@B148]). The expression of D~1~ receptors is higher than that of D~2~ in the cortex (Gaspar et al., [@B49]), and although more prevalent on pyramidal neurons, D~1~ receptors are also widely expressed on GABAergic interneurons (Muly et al., [@B107]). Dopamine in the PFC serves a modulatory purpose and enhances D~1~ associated firing (Cepeda and Levine, [@B26]). Optimal levels of dopamine stimulates cortical GABAergic interneurons, which "tune" the pyramidal firing to sharpen pyramidal signals and enhances cognitive performance (Muly et al., [@B107]).

Cortical interneurons are predominantly GABAergic and prevent aberrant firing of cortical processes by shaping the receptive fields of thalamocorical signals (Jones, [@B82]). In addition, interneurons facilitate feed-forward inhibition, where a single thamalmic fiber can activate its pyramidal target as well as an interneuron, which will inhibit the pyramidal target within 1--10 ms, providing fine temporal control of pyramidal firing (Gabernet et al., [@B48]). These cells are necessary for inhibitory modulation, disinhibitory modulation, discriminative processing, gating of signals, as well as contribute in the generation of oscillatory rhythms that unify pyramidal cell discharge (Benes and Berretta, [@B16]).

3. Acute effects of methamphetamine
===================================

Acute methamphetamine administration causes vesicular release of dopamine from the VTA into the NAc and PFC in the mesolimbic and mesocortical pathways (Fallon and Moore, [@B43]; Haber and Knutson, [@B64]). Methamphetamine also reverses both vesicular monoamine transporter 2 and the dopamine transporter (Sulzer et al., [@B143]; Sora et al., [@B138]) to effectively increase synaptic concentrations of dopamine in the striatum in the nigrostriatal pathway (Bustamante et al., [@B20]; Fowler et al., [@B47]; Haber and Knutson, [@B64]) (Figure [3](#F3){ref-type="fig"}).

![**Methamphetamine effects on dopaminergic pathways**. Methamphetamine causes excessive amounts of dopamine to be released from the substantia nigra pars compacta (SNc) into the striatum (large black arrows), forcing pronounced inhibition of the SNr/GPi (*red and blue*). Dopamine from the VTA to the NAc increases NAc inhibition on the SNr/GPi (*green*). Enhanced cortical signals increases glutamate from the PFC to the NAc (*purple*) further increasing NAc inhibition on the SNr/GPi, and exacerbates glutamate excess in the cortex. CTX, cortex; GABA, gamma-aminobutyric acid; NMDA, N-methyl-D-aspartate; GPe, globus pallidus externa; SNr, substantia nigra pars reticulata; GPi, globus pallidus interna; TH, thalamus; STN, sub thalamic nucleus; NAcc, nucleus accumbens core; VTA, ventral tegmental area. Round structures indicate dopamine cell bodies; star shaped structures indicate GABA cell bodies; triangular structures indicate glutamate cell bodies.](fnhum-08-00537-g0003){#F3}

Acutely, methamphetamine increases levels of glutamate in the striatum (Stephans and Yamamoto, [@B141]) and the PFC (Stephans and Yamamoto, [@B142]). This is achieved via a polysynaptic process, where the increased dopamine release activates gamma-aminobutyric acid (GABA) neurons in the striatum of the direct pathway and increases GABA release at their terminals in the SNr. Pre-synaptic D~1~ receptors on the striatonigral terminals (Altar and Hauser, [@B3]) also enhance GABA release at the SNr (Mark et al., [@B100]). The increased GABA at the SNr cell bodies disinhibit the thalamocortical glutamatergic pathway (Mark et al., [@B100]), which results in an increase of glutamate within the cortex (Timmerman and Westerink, [@B146]). The high levels of glutamate at the level of the cortex activates the glutamatergic corticostriatal neurons via topographically specific postsynaptic density connections (Gerfen, [@B51]; Bellomo et al., [@B15]), and increases glutamate release in the striatum (Stephans and Yamamoto, [@B141]), driving positive feedback.

Glutamate levels in the striatum in fact remain elevated for over 28 h, even after dopamine has returned to basal levels (Mark et al., [@B100], [@B99]). It was found that the vesicular glutamate transporter 1 expression was increased, which allows for the sequestration of glutamate in the cortex, and thus allowing extended glutamate release into the striatum after methamphetamine administration (Mark et al., [@B99]). The NMDA receptors in the striatum facilitate D~1~ receptor mediated currents, which positively drives this circuit.

Acute methamphetamine administration has been found to decrease GABA~B~ transmission within the VTA (Padgett et al., [@B112]), and increases dopamine release from the VTA to the NAc (Fallon and Moore, [@B43]; Kankaanpää et al., [@B85]; Zhang et al., [@B163]). This release of dopamine in the mesolimbic pathway is associated with the experience of reward or euphoria (Volkow et al., [@B153]; Drevets et al., [@B41]), and increases subsequent GABA release to the substantia nigra for longer than 80 min (Sirinathsinghji et al., [@B137]). Inhibition of the SNr disinhibits the thalamocortical glutamatergic pathway, and results in increased cortical glutamate (Mark et al., [@B100]).

Methamphetamine also increases dopamine release from the VTA to the prefrontal cortex in the mesocortical pathway (Fallon and Moore, [@B43]; Stephans and Yamamoto, [@B142]). At low doses, methamphetamine can increase cognitive performance by activation of D~1~ receptors in the PFC (Silber et al., [@B135]), however high doses impair cognitive function (Schroder et al., [@B129]), possibly by over activation of D~1~ receptors on interneurons in the PFC and excessive inhibition of cortical signals (Muly et al., [@B107]).

Methamphetamine can thus increase glutamatergic signals to the cortex from both the nigrostriatal, as well as the mesolimbic reward circuits, and increase dopaminergic signals from the mesocortical pathway. Excessive glutamate and dopamine in the cortex may overwhelm GABAergic interneuons, causing dysregulation of the signals, which may relate to the psychotic symptoms that can occur during methamphetamine intoxication in some individuals.

4. Chronic methamphetamine effects
==================================

Studies in chronic methamphetamine abusers have found several changes in the brain, particularly within the striatum. A post mortem study found decreased levels of dopamine terminal markers such as dopamine, tyrosine hydroxylase, and dopamine transporter in the striatum (Wilson et al., [@B158]). Positron emission tomography research found decreased levels of the dopamine transporter (Volkow et al., [@B152]), decreased D~2~ (Volkow et al., [@B151]) and decreased vesicular monoamine transporter 2 in the striatum (Chang et al., [@B27]). Single photon emission computed tomography studies have found decreased regional cerebral blood flow in chronic methamphetamine abusers (Iyo et al., [@B78]; Chung et al., [@B29]), magnetic resonance spectroscopy found decreased *N*-acetylaspartate (NAA) in the basal ganglia and frontal lobe (Ernst et al., [@B42]; Howells et al., [@B71]), and anterior cingulate (Nordahl et al., [@B111]; Howells et al., [@B71]) indicative of decreased neuronal integrity in these areas.

Participants with MAP have shown decreased P300 amplitude and increased P300 latency, particularly over the frontal cortex in electroencephalography (EEG) event related potential (ERP) studies, which suggests dysfunctional higher cognitive processing (Iwanami et al., [@B74], [@B76], [@B75]). Magnetic resonance spectroscopy showed decreased creatine and phosphocreatine to choline (Cr+PCr/Cho) ratio in the basal ganglia that correlated significantly with increased residual psychiatric symptom severity (Sekine et al., [@B133]). Magnetic resonance imaging processed for voxel based morphometry found decreased frontopolar volumes compared to healthy controls (Aoki et al., [@B7]).

Various regimen of methamphetamine administration have developed different models for MAP and schizophrenia. The neurotoxicity model typically gave high doses of methamphetamine in a short amount of time, and found extensive neurotoxic damage, particularly to the nigrostriatal and mesolimbic systems (Robinson and Becker, [@B123]; Machiyama, [@B97]; Davidson et al., [@B37]; Cadet and Krasnova, [@B21]). However, it has been argued that the severe neurotoxicity produced by this model is not similar to the lack of obvious neurotoxic damage in people with MAP and schizophrenia, in addition methamphetamine abusers tend to begin with low doses of methamphetamine, which have shown to be neuroprotective to subsequent higher doses. Most relevant to this review is the methamphetamine sensitization model, where lower doses of repeated methamphetamine exposure have been shown to produce behavioral effects that best model psychosis by measurements such as increased locomotion, hallucinatory behaviors in the case of non-human primates, pre-pulse inhibition deficits, latent inhibition deficits, other cognitive deficits (Castner and Goldman-Rakic, [@B24]; Castner et al., [@B23]; Kamei et al., [@B84]; Featherstone et al., [@B45]; Nagai et al., [@B108]; Forrest et al., [@B46]). Although, the escalating dose-binge model also appears to model a widely used pattern of drug taking by abusers (Segal and Kuczenski, [@B131], [@B132]).

Methamphetamine sensitized animals showed increased glutamate levels in the VTA 3 days after withdrawal (Giorgetti et al., [@B52]). The enhanced VTA activation increased release of dopamine in the NAc (Gonon, [@B60]) and dorsal striatum with a low dose amphetamine challenge after 28 days of withdrawal (Paulson and Robinson, [@B115]). Glutamate release was found to be increased in the NAc 2 days post withdrawal with low dose amphetamine challenge (Xue et al., [@B159]), or with K^+^ depolarization 1 day post withdrawal (Bustamante et al., [@B20]). Studies in addiction have found that the increased sensitivity of the NAc to glutamate, and the increased glutamate release from the PFC to the NAc, mediates craving, and relapse in response to drug-related cues (Cornish and Kalivas, [@B32]; Kalivas and Volkow, [@B83]). Hyper-sensitivity of the NAc would further increase the activation of the NAc-thalamocortical circuit, and increase cortical glutamate (Maurice et al., [@B101]; Nicola, [@B110]).

Methamphetamine withdrawal after sensitization also exaggerated the inhibitory responses in the medial PFC, while augmenting excitatory responses in the ocular frontal cortex (Homayoun and Moghaddam, [@B69]). Morphological studies have found increased dendritic branching in the NAc and PFC of rodents approximately 1 month after methamphetamine sensitization (Robinson and Kolb, [@B124], [@B125]), while a study in the dorsolateral PFC of non-human primates found decreased dendritic length and branching approximately 3 years after methamphetamine sensitization (Selemon et al., [@B134]). Twelve weeks of repeated low dose amphetamine exposure in rhesus monkeys showed reduced \[123\]IBZM displacement, and thus reduced dopamine release, in the striatum in response to a low dose amphetamine challenge about 30 days post withdrawal (Castner et al., [@B23]). Work on non-human primates has also shown that the cognitive deficits produced by methamphetamine sensitization are related to reduced dopaminergic turnover in the PFC and striatum (Castner et al., [@B25]), mediated by the D1-ERK pathway dysfunction in the PFC (Nagai and Yamada, [@B109]).

While studies in the methamphetamine sensitization model of psychosis is extensive (Featherstone et al., [@B45]), few have examined the effects of chronic methamphetamine exposure on the cortical GABAergic system.

5. Chronic methamphetamine effects on cortical GABA
===================================================

Little research using any model has studied methamphetamine effects on GABA in the cortex, however there is some evidence which indicates that methamphetamine may indeed cause damage to cortical GABAergic interneurons.

Postmortem staining of the cortex in HIV positive methamphetamine users, compared to HIV positive non-users found extensive loss of calbindin immunoreactive interneurons in the cortex (Langford et al., [@B92]). Although co-morbid HIV and methamphetamine is known to compound neurodegenerative effects (Liu et al., [@B96]; Reiner et al., [@B120]), another group also found decreased calbindin immunoreactivity in cortical interneurons in rats that underwent an escalating dose, multiple binge exposure to methamphetamine, without the HIV confound (Kuczenski et al., [@B91]).

The escalating dose, multiple binge exposure of methamphetamine to the rats (0.1 mg/kg escalated in 0.1 mg/kg increments 3 times a day, to 4 mg/kg over 14 days, then 4 injections of 6 mg/kg every 2 h for 11 successive days) in the Kuczenski et al. ([@B91]) study deserves further discussion. The loss of calbindin immunoreactive interneurons was apparent from 3 days after last exposure to methamphetamine, and persisted when examined at 30 days post exposure. Pyramidal neurons and dendrites (marked by NeuN and MAP2 staining, respectively), were not significantly lost at 3 days post exposure, but were significantly reduced at 30 days post exposure, particularly in layers 2, 3, and 5 (Kuczenski et al., [@B91]). These results suggest a particular vulnerability of interneurons to methamphetamine administration, as compared to pyramidal neurons. The contrary observation of loss of pyramidal cells and dendrites in this study and the increased dendritic branching and spine densities in the PFC and NAc as seen in earlier studies (Robinson and Kolb, [@B124], [@B125]) was not discussed. The Kuczenski study appears to be supported by the morphological study in non-human primates that showed decreased dendritic branching in the dorsolateral PFC 3 years post amphetamine sensitization (Selemon et al., [@B134]). Selemon et al. explained possible discrepancies between the primate study and Robinson\'s studies to species differences or interval of methamphetamine discontinuation, however the two rodent studies were both performed in Sprague-Dawley rats, and examined at 30 (Kuczenski et al., [@B91]) or 38 (Robinson and Kolb, [@B124], [@B125]) days post exposure. In addition, the methamphetamine administration regimen was similar, where the Robinson and Kolb study escalated doses of *D*-amphetamine from 1 to 8 mg/kg for 5 weeks excluding weekends, and gave 8 mg/kg doses twice a day, 4 h apart for the last 4 days (Robinson and Kolb, [@B124]). Further work regarding methamphetamine effects on cortical morphometry may be helpful to clarify these discrepancies.

A toxicity study delivered a continuous high dose (32 mg/kg/day) of methamphetamine by implanted minipump in rats for 5 days (Armstrong and Noguchi, [@B9]). Autoradiography of GABA~A~ sites labeled with \[^3^H\]-Flunitrazepam showed that methamphetamine treatment caused a significant general decrease in staining on the entire hemi-brain, and significant decrease in the hippocampus. Other areas that were compared did not show significant decreases compared to drug naïve rats, although there was a general pattern of lower GABA binding in anterior cingulate, caudate, NAc, thalamus, and amygdala (Armstrong and Noguchi, [@B9]). Perhaps an increase in sample size to more than 8 rats in controls, and 7 rats in the methamphetamine treated group may have shown significant decreased \[^3^H\]-Flunitrazepam binding in these areas.

More recent studies have found that methamphetamine sensitization in mice (4 injections of 2 mg/kg, every other day) caused memory impairment, and autoradiography showed decreased \[^3^H\]MK-801 binding to NMDA receptors in the cortex, and hippocampus (Lee et al., [@B93]). Whether NMDA receptors that were lost were expressed on pyramidal or non-pyramidal neurons within the PFC is unclear, and the interval between last methamphetamine exposure and autoradiography was only 24 h, immediately after the passive avoidance test (Lee et al., [@B93]).

A different mouse sensitization study (1 mg/kg every day for 7 days) produced cognitive deficits that were ameliorated by the GABA~B~ receptor agonist baclofen (1--2 mg/kg acute dose) (Arai et al., [@B8]). Baclofen has also been shown to ameliorate methamphetamine induced pre-pulse inhibiton and object recognition memory deficits in mice (Mizoguchi and Yamada, [@B105]). Amphetamine induced dopamine release in the PFC is reduced by baclofen and SKF97541, which activate presynaptic GABA~B~ receptors on dopamine terminals (Balla et al., [@B10]).

A recent magnetic resonance spectroscopy study in methamphetamine sensitized rat brain dissections (2.5 mg/kg twice per day over 7 days) showed decreased GABA, glutamate, and glutamine levels in the PFC (Bu et al., [@B18]). Acute methamphetamine administration showed the ability to sequester glutamate in the cortex for over 28 h through upregulation of VGLUT1 (Mark et al., [@B99]). The Bu et al. study sacrificed the animals within 30 min of the last dose of methamphetamine and one might have expected to find increased glutamate levels in the prefrontal cortex. However, these authors suggest that the reduction in glutamate is likely due to higher demand, while the reduction in GABA was thought to be due both reduced glutamate as a substrate to form GABA, as well as increased GABA metabolism to succinic acid semialdehyde (which was found to be increased) (Bu et al., [@B18]).

Even though there is vast methodological variation in the above studies, each have shown evidence of cortical GABAergic deficit as a result of methamphetamine treatment. Damage to cortical GABAergic function could account for the cognitive impairments and persistent psychosis symptoms in MAP. The mechanism for this deficit is unknown. The present review proposes that there may be particular vulnerability of GABAergic interneurons, that might contribute to these observations of GABA dysfunction in the cortex as a result of methamphetamine exposure.

6. Cortical GABAergic interneuron vulnerability
===============================================

The NMDA receptor is an ionotropic glutamate receptor that consists of a heterotetramer of two NR1 and two NR2 subunits, and mediates excitatory post-synaptic potentials (Dingledine et al., [@B40]). NMDA receptors are distributed widely throughout the nervous system (Petralia et al., [@B117]).

The downstream effect of NMDA receptor function is highly dependent on the location of the receptors. The expression of *N*-methyl-*D*-aspartate (NMDA) receptors on postsynaptic pyramidal neurons leads to activation of the glutamatergic system and downstream neuronal activation. The expression of NMDA receptors on GABAergic interneurons results in a release of GABA, and has a downstream inhibitory effect. Thus, activation of NMDA receptors on pyramidal neurons leads to further release of glutamate, thereby providing positive feedback; while activation of NMDA receptors on interneurons leads to GABA release and regulation of glutamatergic function.

Pyramidal neurons in the cortex primarily express NMDA receptors at the somatic membrane, and proximal dendrites and in post synaptic densities (Aoki et al., [@B6]; Petralia et al., [@B116]), with decreased expression at more distal dendrites (Huntley et al., [@B73]). Cortical GABAergic interneurons have typically multipolar aspiny dendrites (Kawaguchi, [@B87]; DeFelipe, [@B38]), with the majority of NMDA receptors expressed on the dendrites, not close to obvious post synaptic densities (Goldberg et al., [@B54],[@B55]) (Figure [4](#F4){ref-type="fig"}). Dense patterns of NMDAR1 staining appear particularly in the neuropil of layer II and III in the cortex (Aoki et al., [@B6]; Huntley et al., [@B73]), which coincide with the dense dendritic projections of basket, chandelier, and double bouquet type interneurons in this region (Benes and Berretta, [@B16]; DeFelipe, [@B38]; Gentet, [@B50]). Discussions of the various types, morphology, and physiological characterizations of GABAergic interneurons are interesting but not within the scope of this paper, and have been have been thoroughly reviewed elsewhere (Benes and Berretta, [@B16]; DeFelipe, [@B38]; Gentet, [@B50]).

![**NMDA receptor localization in the cortex. (A)** Glutamatergic pyramidal neurons express NMDAreceptors preferentially in the post synaptic density (PSD) region, around the soma, and apical dendrites. Glutamate stimulation causes more focused calcium ion influx, and the cell has lower vulnerability to neurotoxicity **(B)** GABAergic interneurons express NMDA receptors more diffusely over the neuron, often at extrasynaptic locations. Glutamate stimulation causes widespread calcium ion influx, and the cell has greater vulnerability to neurotoxicity.](fnhum-08-00537-g0004){#F4}

The predominance of synaptic NMDA receptors on the pyramidal neurons, and extrasynaptic NMDA receptors on GABAergic interneurons differentiates their vulnerability to neurotoxicity (Papadia and Hardingham, [@B114]). Synaptic and extrasynaptic NMDA receptors have opposite effects regarding cAMP response element binding protein (CREB) function, gene regulation, and neuron survival (Hardingham et al., [@B68]). Calcium ion entry through synaptic NMDA receptors induces CREB activity and brain derived neurotrophic factor (BDNF) gene expression as strongly as those caused by direct stimulation of L-type calcium channels. In contrast, calcium ion entry through extrasynaptic NMDA receptors, triggered by bath glutamate exposure or hypoxic conditions, activates a dominant pathway that blocks CREB and thus BDNF expression. In essence, synaptic NMDA receptors, mostly localized on glutamatergic cells, have anti-apoptotic activity, whereas stimulation of extrasynaptic NMDA receptors on interneurons results in glutamate-induced excitotoxicity (Hardingham et al., [@B68]). Similar CREB inhibiting effects have been found by activation of extrasynaptic NMDA receptors in co-cultured cortical glutamatergic and striatal GABAergic neurons, while synaptic NMDA activation on GABAergic striatal neurons was neuroprotective (Kaufman et al., [@B86]). Details of the mechanisms of the dicotomous effects of synaptic vs. extrasynaptic NMDA receptor activation is reviewed elsewhere (Papadia and Hardingham, [@B114]; Hardingham and Bading, [@B67]). Essentially, lower levels and specific activation of synaptic NMDA receptors promote neuroprotection and inhibits apoptotic pathways; while bath stimulation or over spill from high level stimulation cause extrasynaptic NMDA receptor activation, which not only inhibits CREB and BDNF expression, but also promotes a variety of other pro-death cascades (Papadia and Hardingham, [@B114]; Hardingham and Bading, [@B67]; Petralia, [@B118]).

Activation of predominantly extrasynaptic NMDA receptors on GABAergic interneurons would make these cells more vulnerable to neurotoxicity than pyramidal neurons. Thus, persistent glutamate overflow from the overstimulated thalamus and NAc to the cortex from repeated methamphetamine administration might lead to accelerated damage to interneurons compared to pyramidal neurons. Indeed, an escalating dose multiple binge regimen of methamphetamine administration in rats found that calbindin stained cortical interneurons were more sensitive to methamphetamine toxicity than their NeuN stained pyramidal neurons, as the interneurons were significantly lost from 3 days after the last methamphetamine binge dose, whereas the pyramidal neurons were lost only 30 days after the last dose (Kuczenski et al., [@B91]). Damage to cortical interneurons would diminish the negative feedback on pyramidal neurons, and result in increased subsequent pyramidal firing.

Cortical GABAergic interneurons synchronize cortical processes (Jones, [@B82]; Benes and Berretta, [@B16]). Damage to these neurons, whether by methamphetamine induced neurotoxicity, developmental defect, or other mechanisms would dysregulate glutamate signaling in the cortex. Even transient inhibition of NMDA receptors by a dose of MK-801 that impaired working memory in rats decreased organized bursting activity and increased the number of irregularly discharged single spikes from prefrontal pyramidal neurons (Jackson et al., [@B79]). Aberrant glutamate signals transmitted through the cortico-striatal-thalamo-cortical loop may result in aberrant behaviors, and psychosis.

7. Summary
==========

The development of MAP might ultimately be due to damage of cortical interneurons. Cortical interneurons are likely more vulnerable to neurotoxicity, as they have a higher proportion of extrasynaptically expressed NMDA receptors. Methamphetamine use causes an overflow of dopamine in the striatum, which leads to excessive glutamate release into the cortex. Excess glutamate in the cortex might, over time, cause damage to cortical interneurons. Damage to cortical interneurons dysregulate thalamocortical signals, and might result in the presentation of psychotic symptoms as seen in schizophrenia (Figure [5](#F5){ref-type="fig"}).

![**Summary flow diagram**.](fnhum-08-00537-g0005){#F5}

Studies of GABAergic disturbance in the cortex as a result of methamphetamine have been presented, however further studies that directly compare cell type vulnerabilities to synaptic or extrasynaptic stimulation, as well as measurements of GABA concentrations, receptor expression and sensitivity in the cortex as a result of methamphetamine sensitization or psychosis, would be required to test this hypothesis.
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